业界动态监管公开信息 · FDA

《冠状病毒援助、救济和经济安全法案》(CARES Act)缓解药品短缺的努力

FDA Drugs · 2026-11-13 22:44

正文 · 中文译文

《冠状病毒援助、救济和经济安全法案》(CARES法案)药品短缺缓解工作 药品短缺 药品短缺 | 附加新闻和信息 关于药品短缺的常见问题 药品短缺信息图 最新动态 FDA向已注册的药品生产企业或其授权代理人发出提醒,上述企业尚未提交2025日历年度报告,报告内容为该企业为商业分销而生产、制备、增殖、配制或加工的药品及某些生物制品的数量。药品生产企业应通过NextGen门户中更新后的CARES法案数量信息报告应用程序报告其信息。 未遵守《联邦食品、药品和化妆品法案》第510(j)(3)条年度数量报告要求、且未在2026年12月31日前提交2025日历年度报告的注册人,可能于2027年初被列入FDA.gov网站上发布的所有不合规实体名单。 此外,2026日历年度的药品数量报告应自2027年1月1日起提交至FDA,但不得晚于2027年3月31日。 《冠状病毒援助、救济和经济安全法案》(CARES法案)背景 《冠状病毒援助、救济和经济安全法案》(CARES法案)于2020年3月27日签署成为法律,旨在协助应对工作并缓解COVID-19的经济影响。 除应对COVID-19疫情外,《CARES法案》还包含旨在增强FDA识别、预防和缓解人用和兽用药品可能短缺能力的授权,其方式包括增强FDA对药品和医疗产品供应链的可见性等。药品短缺可能因多种原因发生,包括生产和质量问题、延迟以及停产。药品制造商向FDA提供该机构收到的大部分药品短缺信息,该机构与制造商密切合作以预防或减少短缺的影响。 增强FDA识别、预防和缓解药品短缺能力的具体授权概述如下。 实施《CARES法案》新增的FDA授权 向FDA通报永久停产和生产中断 为药品制定风险管理计划 报告所列人用和兽用药品及人用生物制品生产数量 向FDA通报永久停产和生产中断 《CARES法案》修订了《联邦食品、药品和化妆品(FD&C)法案》,扩大了某些药品制造商的要求,即就可能导致美国供应出现有意义中断的永久停产或生产中断以及此类停产或中断的原因向FDA通报。 FDA发布了一份题为“根据《联邦食品、药品和化妆品法案》第506C条向FDA通报成品或原料药(API)生产中断或停止”的行业指南草案,以协助申请人和制造商就某些成品药和生物制品及某些原料药的生产变更向FDA提供及时、信息丰富的通知。包含详细信息的及时通知使该机构能够评估情况并确定适当的行动方案,以帮助预防或减轻药品短缺。 《新冠病毒援助、救济和经济安全法案》(CARES Act)修订了《联邦食品、药品和化妆品法案》,增加了一项条款,要求《联邦食品、药品和化妆品法案》第506C(a)条所述药物的每位制造商,或任何原料药(API)或用于制备或给药的任何相关医疗器械的每位制造商,酌情制定、维护和实施冗余风险管理计划,该计划针对药物或药物原料药生产的每个场所,识别和评估药物供应风险(如适用)。 FDA发布了一份题为“缓解潜在药品短缺的风险管理计划”的行业指南草案,旨在帮助生产商制定、维护并酌情实施风险管理计划,以主动协助预防人用药品和生物制品短缺。该指南草案适用于对药品生产负有监督和控制责任以确保质量或拥有或运营生产药品或生物制品场所的任何个人或实体。 为药品制定风险管理计划 《CARES法案》修订了《FD&C法案》,增加了一项条款,要求《FD&C法案》第506C(a)节所述药品的每一生产商,或该药品所用任何活性药物成分(API)或任何用于制备或给药的相关医疗器械的每一生产商,针对该药品或该药品的API生产的每一个场所,酌情制定、维护并实施一项冗余风险管理计划,以识别和评估药品供应风险(如适用)。 FDA发布了一份题为“缓解潜在药品短缺风险的管理计划”的行业指南草案,旨在帮助生产商制定、维护并酌情实施风险管理计划,以主动协助预防人用药品和生物制品短缺。该指南草案适用于任何对药品生产负有监督和控制职责以确保质量的人员或实体,或拥有或运营生产药品或生物制品的机构的人员或实体。 报告所列人用和兽用药品及人用生物制品的生产数量 《CARES法案》修订了《联邦食品、药品和化妆品法案》(FD&C法案),要求每一位根据FD&C法案第510条向FDA注册的、涉及人用或兽用药品的人员(包括再包装商和再贴标商),必须每年向FDA报告该人员为商业分销而生产、制备、繁殖、配制或加工的每种所列药品的数量。 通过NextGen门户,FDA建立了一种 drug registrants 及其授权代理人报告所需数据的方式。门户提供了指南和视频,说明如何使用该门户。有关报告的更多信息,可参见《根据FD&C法案第510(j)(3)条报告所列药品和生物制品数量行业指南》以及《报告所列药品和生物制品数量技术符合性指南》。 报告要求适用于每一位依据《联邦食品、药品和化妆品法案》(FD&C法案)第510条向FDA注册的、涉及列入清单药品(包括成品剂型产品、活性药物成分(API)及其他类型列入清单药品,但依据第510(j)(3)(B)条命令豁免的生物制品或生物制品类别除外)的人员。除依据FD&C法案第505条批准的人用药品、依据第512条批准的兽用药品、依据第571条有条件批准的兽用药品或依据第572条编入索引的兽用药品外,指南中描述的流程同样适用于对其他列入清单药品的此类报告,包括FD&C法案第575条所定义的医用气体、标示为顺势疗法的药品、依据FD&C法案第505G条要求上市的药品(通常称为非处方药专论药品),以及未依据FD&C法案第512条、第571条和第572条获得批准、有条件批准或编入索引的兽用药品。 请访问我们的药品数量报告网页,获取尚未提交2024日历年度报告的公司名单。 NextGen资源 NextGen门户 NextGen门户注册指南 列入清单药品和生物制品数量报告参考指南 CSV模板成品包装形式药品CSV模板 成品包装形式药品CSV模板说明 成品包装形式药品自定义CSV模板说明 非成品包装形式药品CSV模板 非成品包装形式药品的CSV模板说明 自定义CSV模板的非成品包装形式药品说明 原料药CSV模板 原料药CSV模板说明 原料药自定义CSV模板说明 监管信息 根据《联邦食品、药品和化妆品法案》第510(j)(3)条报告已上市药品和生物制品数量指南 已上市药品和生物制品数量报告技术一致性指南 命令:豁免某些类别生物制品根据《联邦食品、药品和化妆品法案》的某些报告要求 网络研讨会 从CSV文件上传药品数量数据 手动录入原料药 手动录入多层级的成品包装形式药品 手动录入非成品包装形式药品 手动录入单层级的成品包装形式药品 附加信息 有关提交过程的技术支持问题应发送至CDER NextGen门户内基于Salesforce的帮助中心。 有关报告内容的问题,请联系(CDER)DrugAmountReporting@fda.hhs.gov,(CBER)沟通、外联与发展办公室,800-835-4709或240-402-8010,或(CVM)监督与合规办公室,240-402-7082或CVMSurveillance@fda.hhs.gov(视情况适用)。 内容截至日期: 2026年11月13日 受监管产品 药品

正文 · 英文原文

Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Drug Shortage Mitigation Efforts Drug Shortages Drug Shortages | Additional News and Information Frequently Asked Questions about Drug Shortages Drug Shortages Infographic What’s New FDA sent a reminder to registered drug establishments, or their authorized agents, that have not submitted a calendar year 2025 report on the amount of drugs and certain biological products the establishment manufactured, prepared, propagated, compounded or processed for commercial distribution. Drug establishments should report their information through the updated CARES Act Amount Information Reporting application in the NextGen Portal. Registrants who fail to comply with the annual amount reporting requirement under section 510(j)(3) of the FD&C Act and do not submit calendar year 2025 reports by December 31, 2026, may be added to a list posted on FDA.gov with all noncompliant entities in early 2027. Additionally, drug amount reports for calendar year 2026 should be submitted to FDA starting on Jan. 1, 2027, but no later than March 31, 2027. Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Background The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law on March 27, 2020, to aid response efforts and ease the economic impact of COVID-19. In addition to the COVID-19 response efforts, the CARES Act included authorities intended to enhance FDA’s ability to identify, prevent, and mitigate possible shortages of human and animal drugs by, among other things, enhancing FDA’s visibility into the drug and medical product supply chains. Drug shortages can occur for various reasons, including manufacturing and quality problems, delays, and discontinuations. Drug manufacturers provide FDA with most of the drug shortage information the agency receives, and the agency works closely with manufacturers to prevent or reduce the impact of shortages. The specific authorities to enhance FDA’s ability to identify, prevent, and mitigate drug shortages are summarized below. Implementation of New FDA Authorities added by the CARES Act Notifying FDA of Permanent Discontinuances and Interruptions in Manufacturing Creating Risk Management Plans for Drugs Reporting the Amount of Listed Human and Animal Drugs and Human Biological Products Manufactured Notifying FDA of Permanent Discontinuances and Interruptions in Manufacturing The CARES Act amended the Federal Food, Drug, and Cosmetic (FD&C) Act to expand the requirement for manufacturers of certain drugs to notify FDA about permanent discontinuances in manufacturing or interruptions in manufacturing that are likely to lead to a meaningful disruption in supply in the United States, and the reasons for such discontinuances or interruptions. FDA issued a draft guidance for industry titled, “Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients (API) Under Section 506C of the FD&C Act” to assist applicants and manufacturers in providing FDA with timely, informative notifications about changes in the production of certain finished drugs and biological products and certain APIs. Timely notifications that include detailed information allow the agency to evaluate the situation and determine an appropriate course of action to help prevent or mitigate drug shortages. The CARES Act amended the FD&C Act to include a provision requiring each manufacturer of a drug described in section 506C(a) of the FD&C Act or of any active pharmaceutical ingredient (API) or any associated medical device used for preparation or administration included in the drug to develop, maintain, and implement, as appropriate, a redundancy risk management plan that identifies and evaluates risks to the supply of the drug, as applicable, for each establishment in which the drug or API of the drug is manufactured. FDA issued a draft guidance for industry titled, “Risk Management Plans to Mitigate the Potential for Drug Shortages” intended to help manufacturers develop, maintain, and implement, as appropriate, risk management plans to proactively assist in the prevention of human drug product and biological product shortages. This draft guidance is relevant to any person or entity who has oversight and control over the manufacture of drugs to ensure quality or owns or operates an establishment that manufactures a drug or biological product. Creating Risk Management Plans for Drugs The CARES Act amended the FD&C Act to include a provision requiring each manufacturer of a drug described in section 506C(a) of the FD&C Act or of any active pharmaceutical ingredient (API) or any associated medical device used for preparation or administration included in the drug to develop, maintain, and implement, as appropriate, a redundancy risk management plan that identifies and evaluates risks to the supply of the drug, as applicable, for each establishment in which the drug or API of the drug is manufactured. FDA issued a draft guidance for industry titled, “Risk Management Plans to Mitigate the Potential for Drug Shortages” intended to help manufacturers develop, maintain, and implement, as appropriate, risk management plans to proactively assist in the prevention of human drug product and biological product shortages. This draft guidance is relevant to any person or entity who has oversight and control over the manufacture of drugs to ensure quality or owns or operates an establishment that manufactures a drug or biological product. Reporting the Amount of Listed Human and Animal Drugs and Human Biological Products Manufactured The CARES Act amended the FD&C Act to require that each person (including repackers and relabelers) who registers with FDA under section 510 of the FD&C Act with regard to a human or animal drug must report annually to FDA the amount of each listed drug that was manufactured, prepared, propagated, compounded, or processed by such person for commercial distribution. Through the NextGen Portal, FDA has established a way through which drug registrants and their authorized agents should report the required data. There are guides and videos to provide instructions for how to use the portal. Further information about reporting can be found in the Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act Guidance for Industry and the Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide. The reporting requirements apply to each person who registers with FDA under section 510 of the FD&C Act with regard to a listed drug (including a finished dosage form product, an active pharmaceutical ingredient (API), and other types of listed drugs, except for biological products or categories of biological products exempted by an order under section 510(j)(3)(B)). In addition to human drugs approved under section 505 of the FD&C Act, and animal drugs approved under section 512, conditionally approved under section 571 or indexed under section 572 of the FD&C Act, the process described in the guidance also applies to such reporting with respect to other listed drugs including medical gases, as defined in section 575 of the FD&C Act, drugs labeled as homeopathic, drugs marketed in accordance with requirements under section 505G of the FD&C Act, often referred to as Over-the-Counter Monograph drugs, and animal drugs that are not approved, conditionally approved, or indexed under sections 512, 571, and 572 of the FD&C Act. Visit our drug amount report webpage for lists of companies that have not provided their report for calendar year 2024. NextGen Resources NextGen Portal NextGen Portal Registration Guide Reference Guide for Reporting Amount of Listed Drugs and Biological Products CSV TemplatesCSV template for Drug Products in Finished Package Form Instructions for Drug Products in Finished Package Form CSV template Instructions for Drug Products in Finished Package Form Custom CSV template CSV template for Drug Products Not in Finished Package Form Instructions for Drug Products Not in Finished Package Form for CSV template Instructions for Drug Products Not in Finished Package Form for Custom CSV template CSV template for Active Pharmaceutical Ingredient Instructions for Active Pharmaceutical Ingredient CSV template Instructions for Active Pharmaceutical Ingredient Custom CSV template Regulatory Information Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act Guidance Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide Order: Exemption of Certain Categories of Biological Products From Certain Reporting Requirements Under the Federal Food, Drug, and Cosmetic Act Webinars Uploading Drug Amount Data from CSV File Manual Entry Active Pharmaceutical Ingredient Manual Entry Drug Products in Finished Package Form Multi Level Manual Entry Drug Products Not in Finished Package Form Manual Entry Drug Products in Finished Package Form Single Level Additional Information Technical support questions regarding the submission process should be sent to the Salesforce-based Help Center within the CDER NextGen Portal. For questions regarding report content, please contact (CDER) DrugAmountReporting@fda.hhs.gov, (CBER) Office of Communication, Outreach and Development, 800-835-4709 or 240-402-8010, or (CVM) Office of Surveillance and Compliance, 240-402-7082 or CVMSurveillance@fda.hhs.gov, as applicable. Content current as of: 11/13/2026 Regulated Product(s) Drugs

English
Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Drug Shortage Mitigation Efforts
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界